Earnings Preview For Plains GP Holdings

Plains GP Holdings (NASDAQ:PAGP) is set to give its latest quarterly earnings report on Friday, 2023-08-04. Here’s what…

Plains GP Holdings (NASDAQ:PAGP) is set to give its latest quarterly earnings report on Friday, 2023-08-04. Here’s what investors need to know before the announcement.

Analysts estimate that Plains GP Holdings will report an earnings per share (EPS) of $0.14.

Plains GP Holdings bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company missed EPS by $0.26, which was followed by a 0.0% drop in the share price the next day.

Here’s a look at Plains GP Holdings’s past performance and the resulting price change:

Quarter Q1 2023 Q4 2022 Q3 2022 Q2 2022
EPS Estimate 0.67 0.61 0.46 0.47
EPS Actual 0.41 0.23 0.36 0.30
Price Change % 5.39% -1.14% 3.25% 2.38%

eps graph

Stock Performance

Shares of Plains GP Holdings were trading at $15.19 as of August 02. Over the last 52-week period, shares are up 35.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Plains GP Holdings visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Recap: CSG Systems Intl Q2 Earnings

CSG Systems Intl (NASDAQ:CSGS) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings CSG Systems Intl reported in-line EPS of $0.84 versus an estimate of $0.84.

CSGS

Read More

Orthopedic Devices Maker Treace Medical Concepts’ Gloomy Forecast Cast Concerns Over Long-Term Viability

Treace Medical Concepts reports Q1 EPS loss of $(0.30), sales hit $51.11 million, up 21%. Surge in procedure kits sold due to expanded surgeon base and product mix shift. FY24 sales guidance adjusted to $201M-$211M. Analysts downgrade, citing competitive challenges.

TMCI